Carmat news

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical needby providing a therapeuticalternative to people suffering from end-stage biventricular heart failure,issues an update on its activities and outlook.

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces the completion of investigations on its prostheses.

Following the occurrence of a quality issue affecting some of its prostheses, CARMAT had announced, on December 3, 2021, the voluntary and temporary suspension of impla

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,announces that it has voluntarilysuspended, on a temporary basis, theimplants of its Aeson® artificial heart.

Following  the  occurrence  of  a qualityissueaffecting  some  of  its  pr

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,announces the first implant of theAeson artificial heart in The Netherlands.

The implant procedure was performed by theHeart Team led byDr.Faiz Z. Ramjankhanand Dr.Niels P. van der Kaaij, Cardiothoracicsurgeons,and Dr. Linda W.

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,announces the publication of an articleon the Aeson’s autoregulation system in the October 2021 issue of the ASAIO Journal, a peer reviewed publication of the American Society for Artificial Internal Organs.

The

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that it has received final approval from the Patient Protection Committee (CPP Ile-de-France XI) for the use of the commercial version of the Aeson® heart in the EFICAS study in France.

This agreement from the

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces the appointment of Ivo Simundic as Sales director for the DACH region (Germany, Austria and Switzerland).

Graduated from University of Applied Sciences in Ulm in Mechanical Engineering and holding an MBA in Corp

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its Aeson® bioprosthetic artificial heart in a commercial setting.

This new commercial implant of the Aeson® device was performed by Prof. Assad Haneya and his team of the Department of Cardiovascular Surgery at Univers

The implant was performed at UofL Health – Jewish Hospital by University of Louisville physicians within the framework of the U.S. Early Feasibility Study.

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces the second center implanting its bioprosthetic artificial

The implant was performed at Hannover Medical School.

Paris, July 26, 2021 – 6:00 pm CEST

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the first implant of its Aeson® bioprosthetic artificial heart in Germany.